Kyverna Therapeutics

KEI Comments on Exclusive License to Kyverna Therapeutics

Posted on by Claire Cassedy

On March 2, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention… Continue Reading →

KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy

Posted on by Claire Cassedy

(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading →